MicroRNA-615 functions as a tumor suppressor in osteosarcoma through the suppression of HK2

LIMIN SUN1, PENG WANG1, ZHIQIANG ZHANG1, KAI ZHANG1, ZHENG XU1, SIYUAN LI1 and JUNSHENG MAO2

1Department of Orthopedics, Shandong Provincial Third Hospital, Jinan, Shandong 250031;
2Department of Orthopedic Surgery, Taishan Hospital of Shandong Province, Tai’an, Shandong 271000, P.R. China

Received January 22, 2020; Accepted August 12, 2020

DOI: 10.3892/ol.2020.12089

Abstract. At present, the regulatory mechanisms of various microRNAs (miRNAs/miRs) have been elucidated in human cancers including osteosarcoma (OS). This study mainly focused on the role of miR‑615 in OS, which has not yet been reported. Ninety‑two OS tissues and normal samples were used in this study. Human osteoblast hFOB1.19 cells and OS cell line HOS were utilized to detect the expression of miR‑615. The expression of miR‑615 and gene expression were assessed by RT‑qPCR and western blot analysis. Transwell, MTT and luciferase reporter assays were used to investigate the regulatory mechanism of miR‑615 in OS. The results revealed that miR‑615 expression was reduced in OS tissues and cells, and was associated with poor clinical outcomes and prognosis in OS patients. In addition, overexpression of miR‑615 restrained cell viability and metastasis in OS. Furthermore, hexokinase 2 (HK2) was confirmed as a direct target of miR‑615. Upregulation of HK2 was detected in OS tissues. The upregulation of HK2 weakened the tumor‑suppressive effect of miR‑615 in OS. Moreover, miR‑615 blocked epithelial‑mesenchymal transition (EMT) and inactivated the PI3K/AKT pathway in OS. To conclude, miR‑615 acts as a tumor suppressor in OS, thus miR‑615 can be used as a target for OS treatment.

Introduction

Osteosarcoma (OS) is a malignant tumor that originates in bones, especially in children and adolescents. In addition, OS accounts for about 5% of all childhood tumors (1). Due to the high malignancy of OS and poor prognosis, patients may develop lung metastases within a few months or weeks. The 3- to 5-year survival rate of OS patients with amputation is usually between 5 and 20% (2). The key factors affecting the prognosis of OS are early diagnosis, complete tumor resection, chemotherapy and radiotherapy before and after surgery (3). In addition, it is also related to the tissue type, size and local lymph node status of the tumor cells (4). Although existing treatment methods have greatly improved the survival rate of OS patients, new and effective treatment methods are still needed.

MicroRNAs (miRNAs/miRs) are highly conserved endogenous RNAs, which play important regulatory roles in human cancers (5). It has been found that miRNAs are involved in biological activity through a complex regulatory network. This complex regulatory network can regulate multiple genes involved in cellular activities through an miRNA, and can also finely regulate a gene through the interaction of multiple miRNAs (6). In particular, it has been found that miRNAs can exhibit regulatory effect on bone cancers (7). For example, miR‑214 was found to function as an oncogene in human OS by targeting TRAF3 (8). In contrast, miR‑876‑5p inhibited cell viability and metastasis in OS by targeting c‑Met (9). Recently, the different roles of miR‑615 in human cancers have attracted our attention. Upregulation of miR‑615 has been found in gastric cancer. Moreover, overexpression of miR‑615 was found to promote cell proliferation and migration and inhibit apoptosis in gastric cancer (10). However, downregulation of miR‑615 was found in non‑small cell lung cancer and renal cell carcinoma (11,12). In addition, miR‑615 was found to play an inhibitory role in esophageal squamous cell carcinoma by targeting IGF2 (13). These findings indicate that miR‑615 has a tissue‑specific function in different types of cancer. At present, the specific role of miR‑615 in OS is unclear and needs to be investigated.

As an important regulator, hexokinase 2 (HK2) has been found to be involved in various human cancers, such as laryngeal carcinoma and liver cancer (14,15). In detail, upregulation of HK2 was detected in hepatocellular carcinoma and breast cancer (16,17). Functionally, knockdown of HK2 was found to inhibit the growth of lung carcinoma A549 cells (18). In addition, it was found that upregulation of HK2 promoted the proliferation of ovarian cancer cells (19). Lu et al demonstrated that miR‑603 inhibited the malignancy of ovarian cancer cells by targeting HK2 (20). However, the relationship between HK2 and miR‑615 has not been reported in previous studies.
In addition, the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/HK2 axis has been proposed to regulate the development of breast cancer (21). It has been suggested that the PI3K/AKT pathway is involved in the regulation of tumorigenesis, such as renal cancer and esophageal squamous cell carcinoma (22,23). Xu et al demonstrated that miR-149 inhibited cell growth by regulating the PI3K/AKT pathway in human OS (24). Therefore, the effect of miR-615 on HK2 expression and the PI3K/AKT pathway was also explored in OS. More importantly, the effect of miR-615 on OS cell viability and metastasis was investigated in this study. The present study facilitates the understanding of the pathogenesis of OS.

Materials and methods

Clinical tissues. A total of 92 paired OS tissues were collected from OS patients (60 males and 32 females, mean age 21 years, range from 14 to 35 years) who had undergone resection between January 2017 and January 2019 at the Shandong Provincial Third Hospital. Moreover, all OS patients underwent surgery, and none of them received preoperative radiotherapy or chemotherapy. All of the patients provided informed consents. Approval for this research was acquired from the Institutional Ethics Committee of Shandong Provincial Third Hospital (2016SPT-44).

Cell culture. Human osteoblast hFOB1.19 cells (CRL-11372) and OS cell line HOS (CRL-1543) were purchased from the American Type Culture Collection (ATCC). The cells were incubated in RPMI-1640 medium, supplemented with 10% fetal bovine serum (FBS) and 100 U/ml penicillin-streptomycin (all from HyClone; GE Healthcare). The cells were cultured at 37˚C in a humidified incubator containing 5% CO2.

Cell transfection. miR-615 mimics (5'-UCC GAG CCU GGG UCU UCC GCUCU UCU-3'), mimics-NC (5'-UUC UCAGA CAGGC UCACGUU UUUC-3') miR-615 inhibitor (5'-ACCGA UCGAAGG AUACCC ACA A-3'), inhibitor-NC (5'-CAGA CUU UGGGU GAUACAA A-3'), and the HK2 overexpression plasmid were obtained from GenePharma. These sequences and plasmid were transfected into HOS cells using Lipofectamine 2000 (Invitrogen; Thermo Fisher Scientific, Inc.). The miScript Reverse Transcription kit (Qiagen) based on the manufacturer's instructions. In brief, cells were collected 48 h after transfection. For RT-qPCR and western blot analysis, cells were collected 24 and 48 h after transfection. For the dual luciferase assay, cells were collected 48 h after transfection.

RNA isolation and RT-qPCR. Total RNA isolation was performed using Trizol reagent (Invitrogen; Thermo Fisher Scientific, Inc.). The miScript Reverse Transcription kit (Qiagen) was then used to obtain cDNA solution. RT-qPCR assay was performed using the miScript SYBR®-Green PCR kit (Qiagen) based on the manufacturer's instructions. In brief, 20 µl mixtures were heated at 95˚C for 3 min for enzyme activation, then the 20 µl reaction mixture was incubated as follows: 95˚C for 3 sec and 61˚C for 20 sec for 40 cycles. U6 or GAPDH was used as a control for miR-615 or HK2. The expression levels of miR-615 and HK2 were quantified using the 2⁻ΔΔCq method (25). The forward primer for miR-615 was 5'-CTG CCTTTCACCTTGGGAGAC-3', and the reverse primer was 5'-CGTTTCTGGGGATGAGATA-3'. The internal control GAPDH was forward, 5'-CCGAGTCAACGGAATTGTGTCG TAT-3' and reverse, 5'-AGCCTTCTCCATGTGGTTGAA GAC-3'. The primers for HK2 were 5'-CTCTTTCACGGA GCTCAACC-3' (forward) and 5'-AAGCCCTTCTCCTCAT CTCTC-3' (reverse). The internal control was U6 (forward, 5'-CTCGGTCTTCCGAGCACACA-3' and reverse, 5'-AACGCT TCAGGAATTGTGCT-3').

Transwell assay. For the invasion assay, Matrigel (BD Biosciences) was diluted 1:4 with serum-free DMEM and used to coat the Transwell inserts (pore size, 8-µm; EMD Millipore) to form a matrix barrier. For the migration assay, transfected cells were suspended in FBS-free DMEM containing 0.1% bovine serum albumin (BSA) (Bioworld Technology, Inc.). After 30 min, HOS cell suspension (3x104 cells/well) was added to the Transwell upper chamber, and RPMI-1640 medium (10% FBS) was added to a 24-well plate in the lower chamber. After 24 h, the cells that had migrated or invaded through the membrane were fixed with 95% ethyl alcohol for 15 min at room temperature and stained with 0.1% crystal violet for 10 min at room temperature. Observation and photographing were performed using a light microscope (magnification, x200).

MTT assay. First, the transfected HOS cells (4x104 cells/well) were prepared in a 96-well plate. Then, HOS cells were incubated for 24, 48, 72 or 96 h in fresh medium, respectively. After that, 10 µl of MTT solution was added to incubate the cells for 4 h. Next, the supernatant fractions were discarded, and 150 µl dimethyl sulfoxide (DMSO) was added to each well to dissolve the crystals. The absorbance at 490 nm was examined using a spectrophotometric plate reader (Olympus Corp.).

Dual luciferase reporter assay. First, wild-type WT-HK2-3'UTR or mutant MUT-HK2-3'UTR was inserted into pmirGLO luciferase reporter vector (Promega Corp.). Next, a total of 4x104 HOS cells were seeded per well into 6-well plates and co-transfected with either 50 nM miR-615-3p mimics or mimics-NC and 2 µg plasmid vector using Lipofectamine®  2000, according to the manufacturer's protocol. The cells were lysed and assayed for luciferase activity at 48 h post-transfection using a Dual-Luciferase Assay kit (cat. no. E1910, Promega Corp.). The firefly luciferase was used as a reference for normalization.

Western blot analysis. Protein samples were obtained using RIPA lysis buffer (Beyotime Institute of Biotechnology). Next, proteins were separated by 10% SDS-PAGE. A total of 30 µg protein samples were transferred to the PVDF membrane and were blocked with 5% skim milk. The protein samples were incubated with E-cadherin (rabbit monoclonal; dilution, 1:1,000; cat. no. ab1416; Abcam), N-cadherin (rabbit polyclonal; dilution, 1:1,000; cat. no. ab18203; Abcam), vimentin (rabbit monoclonal; dilution, 1:1,000; cat. no. ab217673; Abcam), PI3K (rabbit monoclonal; dilution, 1:1,000; cat. no. ab32089; Abcam), phosphorlated (p)-PI3K (rabbit monoclonal; dilution, 1:1,000; cat. no. ab154598; Abcam), AKT (rabbit polyclonal; dilution, 1:1,000; cat. no. ab8805; Abcam), p-AKT (rabbit monoclonal; dilution, 1:1,000; cat. no. ab81283; Abcam) and GAPDH (rabbit
monoclonal; dilution, 1:1,000; cat. no. ab181602; Abcam) primary antibodies overnight at 4°C. After that, horseradish peroxidase-conjugated secondary antibodies (dilution, 1:5,000; cat. no. ab7090; Abcam) were added and the protein samples were incubated for 1 h. Protein bands were assessed using an ECL kit (Beyotime Institute of Biotechnology).

**Statistical analysis.** The data were analyzed by SPSS 17.0 (SPSS, Inc.) or Graphpad Prism 6 (GraphPad Software, Inc.). Data are shown as mean ± SD. Differences between groups were analyzed using Student’s t-test or one-way analysis of variance with Tukey’s post hoc test. The relationship between miR-615 expression and the clinicopathological characteristics in OS patients was analyzed by Chi-square test. The univariate Kaplan-Meier method with log-rank test was used to calculate the overall survival rate and survival difference. P<0.05 was considered as indicative of statistical significance.

**Results**

**Downregulation of miR-615 is related to poor clinical outcomes in OS patients.** The expression of miR-615 was detected in OS tissues and cells by RT-qPCR. It was found that miR-615 expression in OS tissues was downregulated compared to that noted in the normal tissues (P<0.01; Fig. 1A). Similarly, the expression of miR-615 in HOS cells was lower than that in the hFOB1.19 cells (P<0.01; Fig. 1B). Next, we found that the low expression of miR-615 was associated with TNM stage and lymph node metastasis in OS patients (P<0.05; Table I). In addition, low miR-615 expression was associated with reduced overall survival of the OS patients (P=0.036; Fig 1C). These results indicate that miR-615 may be involved in the tumorigenesis of OS.

miR-615 inhibits cell viability and metastasis in OS. Next, miR-615 mimics or inhibitor was transfected into HOS cells to explore the function of miR-615 in OS. RT-qPCR showed that the expression of miR-615 was increased by its mimics and reduced by its inhibitor in HOS cells (P<0.01; Fig. 2A). Functionally, overexpression of miR-615 inhibited cell proliferation in the HOS cells. In contrast, downregulation of miR-615 promoted the proliferation of HOS cells when compared to the NC group (P<0.05 or P<0.01; Fig. 2B). In addition, miR-615 mimics suppressed cell migration, while miR-615 inhibitor promoted cell migration in HOS cells when compared to the NC group (P<0.01; Fig. 2C). Consistently, cell invasion was also inhibited by miR-615 mimics and promoted by miR-615 inhibitor in HOS cells when compared to the NC group (P<0.01; Fig. 2D). These results indicate that miR-615 functions as a tumor suppressor in the pathogenesis of OS.

miR-615 directly targets HK2. In addition, TargetScan database (http://www.targetscan.org) indicated that miR-615 has a

| Characteristics                  | Cases | High | Low | P-value |
|----------------------------------|-------|------|-----|---------|
| Age (years)                      |       |      |     |         |
| ≥18                              | 56    | 20   | 36  | 0.83    |
| <18                              | 36    | 11   | 25  |         |
| Sex                              |       |      |     | 0.27    |
| Male                             | 60    | 25   | 35  |         |
| Female                           | 32    | 6    | 26  |         |
| Tumor size (cm)                  |       |      |     | 0.08    |
| <5                               | 63    | 22   | 41  |         |
| ≥5                               | 29    | 9    | 20  |         |
| TNM stage                        |       |      |     | 0.01*   |
| I-II                             | 71    | 26   | 45  |         |
| III-IV                           | 21    | 5    | 16  |         |
| Lymph node metastasis            |       |      |     | 0.01*   |
| No                               | 75    | 26   | 49  |         |
| Yes                              | 17    | 5    | 12  |         |

Statistical analyses were performed by the χ² test. *P<0.05 is considered significant. OS, osteosarcoma.
SUN et al: microRNA-615 FUNCTIONS AS A TUMOR SUPPRESSOR IN OS

binding site that binds to the 3′-UTR (3′-untranslated region) of HK2 (Fig. 3A). Next, this prediction was verified by luciferase reporter assay. We found that miR-615 mimics reduced the luciferase activity of WT-HK2 (P<0.01; Fig. 3B). However, the luciferase activity of Mut-HK2 was not affected by miR-615 mimics in the HOS cells. Then, HK2 expression levels were observed in HOS cells with miR-615 mimics or inhibitor. We found that HK2 expression was significantly reduced by miR-615 mimics and was significantly promoted by miR-615 inhibitor in HOS cells (P<0.01; Fig. 3C). Consequently, the expression of HK2 was examined in OS tissues to explore the dysregulation of HK2 in the progression of OS. Compared to normal tissues, HK2 expression was significantly upregulated in the OS tissues (P<0.01; Fig. 3D). In addition, miR-615 was negatively correlated with HK2 expression in the OS tissues (P<0.0001, R²=0.7319; Fig. 3E). Taken together, miR-615 directly targets HK2 and negatively regulates its expression in OS.

miR-615 is involved in OS progression through targeting HK2.

To explore the interaction between miR-615 and HK2 in OS, HK2 overexpression vector was transfected into HOS cells with miR-615 mimics. First, the decreased expression of HK2 induced by miR-615 mimics was recovered by upregulation of HK2 in HOS cells (Fig. 4A). Similarly, overexpression of HK2 weakened the inhibitory effect of miR-615 on cell proliferation in HOS cells (P<0.01; Fig. 4B). Consistently, upregulation of HK2 also weakened the inhibitory effect of miR-615 on cell migration and invasion in HOS cells (P<0.01; Fig. 4C and D). These findings indicate that upregulation of HK2 impairs the tumor-suppressive effect of miR-615 in OS.

miR-615 blocks EMT and participates in the PI3K/AKT pathway in OS.

Finally, the effect of miR-615 on EMT and the PI3K/AKT pathway in HOS cells was investigated to elucidate the molecular mechanisms of miR-615 in OS. The above results showed that miR-615 regulates cell migration and invasion in OS. Thus, we hypothesized that miR-615 may regulate cell metastasis by mediating EMT. N-cadherin, E-cadherin and vimentin are EMT-associated proteins. We investigated whether miR-615 regulates EMT by detecting the effect of miR-615 on N-cadherin, E-cadherin and vimentin expression. First, overexpression of miR-615 was found to suppress N-cadherin and vimentin expression in the HOS cells. In contrast, downregulation of miR-615 promoted N-cadherin and vimentin expression (Fig. 5). In addition, E-cadherin expression was promoted by miR-615 overexpression and reduced by miR-615 downregulation in HOS cells (Fig. 5).
In addition, the expression levels of PI3K, p-PI3K, AKT and p-AKT involved in the PI3K/AKT pathway were detected in HOS cells with miR-615 mimics or inhibitor. The expression levels of phosphorylated (p-)PI3K and p-AKT were suppressed by miR-615 mimics and promoted by miR-615 inhibitor in HOS cells (Fig. 5). However, PI3K and AKT expression levels were not affected by miR-615 mimics or inhibitor in HOS cells (Fig. 5). Based on these results, miR-615 can block EMT and inactivate the PI3K/AKT pathway in OS.

Discussion

Many miRNAs have been found to participate in the pathogenesis of osteosarcoma (OS) by acting as tumor suppressors or promoters. For example, miR-493-5p was found to inhibit OS cell proliferation and metastasis by targeting Kruppel-like factor 5 (KLF5) (26). Similarly to the above study, miR-615 mimics and promoted by miR-615 inhibitor in HOS cells (Fig. 5). However, PI3K and AKT expression levels were not affected by miR-615 mimics or inhibitor in HOS cells (Fig. 5). Based on these results, miR-615 can block EMT and inactivate the PI3K/AKT pathway in OS.

Figure 3. HK2 is a direct target gene of miR-615. (A) The binding site between miR-615 and HK2. (B) Luciferase reporter assay. **P<0.01, compared with the negative control (NC) group. (C) HK2 expression in HOS cells following transfection with the miR-615 mimics or inhibitor. **P<0.01 compared with the mimics-NC or inhibitor-NC group. (D) HK2 expression was detected in OS tissues and normal tissues. **P<0.01, OS tissues compared with normal tissues. (E) A negative correlation between miR-615 and HK2 was found in OS tissues. HK2, hexokinase 2; OS, osteosarcoma; WT, wild-type; MUT, mutant.
SUN et al: microRNA-615 FUNCTIONS AS A TUMOR SUPPRESSOR IN OS

SUN et al: microRNA-615 FUNCTIONS AS A TUMOR SUPPRESSOR IN OS

6

poor prognosis in patients with glioblastoma (29), which is similar to our results. Functionally, miR-615 has been reported to suppress cell proliferation and invasion in prostate cancer by directly targeting cyclin D2 (30). Moreover, miR-615-3p was found to suppress tumor growth and metastasis in NSCLC by inhibiting IGF2 (31). miR-615 was also found to restrain the proliferation of breast cancer cells by downregulation of AKT2 (32). Consistent with previous studies, we also found that miR-615 inhibited cell proliferation, invasion and migration in OS. However, there are still some limitations in the present study. Further in-depth study should be conducted at the cellular level, such as cell cycle distribution and apoptosis experiments. Moreover, miR-615 regulated the progression of OS by blocking EMT and inactivating the PI3K/AKT pathway, which has not been reported in previous studies. To make our results more convincing, we will design experiments to

Figure 4. miR-615 is involved in OS progression through targeting HK2. (A) HK2 expression was determined in HOS cells following transfection with the miR-615 mimics and HK2 vector. **P<0.01, compared with the Blank group. (B) Cell proliferation, (C) migration and (D) invasion were assessed in HOS cells following transfection with the miR-615 mimics and HK2 vector. **P<0.01, compared with the Blank group. HK2, hexokinase 2; OS, osteosarcoma.

Figure 5. miR-615 blocks EMT and participates in the PI3K/AKT pathway in OS. The protein expression levels of E-cadherin, N-cadherin, vimentin, PI3K, p-PI3K, AKT and p-AKT were detected in HOS cells by western blot analysis following transfection with the miR-615 mimics or inhibitor. EMT, epithelial-mesenchymal transition; PI3K, phosphoinositide 3-kinase; AKT, protein kinase B; OS, osteosarcoma; p-, phosphorylated.

Figure 6. Simple regulatory mechanism of miR-615 in OS is shown in the schematic diagram. HK2, hexokinase 2; EMT, epithelial-mesenchymal transition; PI3K, phosphoinositide 3-kinase; AKT, protein kinase B; OS, osteosarcoma; p-, phosphorylated.
In the present study, we found that miR-615 inhibited the development of OS by targeting HK2. As a tumor promoter, HK2 was also confirmed to be a direct target of miR-218 in glioma (33). Here, a negative correlation between miR-615 and HK2 expression was also identified in OS tissues. Similarly, it has been demonstrated that overexpression of miR-9, miR-98, and miR-199 is correlated with the downregulation of HK2 in colorectal cancer (34). More importantly, upregulation of HK2 impaired the tumor-suppressive effect of miR-615 in OS. The same interaction between HK2 and other miRNAs, such as miR-125b and miR-143, have also been identified in human cancers (35,36). In OS, upregulation of HK2 has been reported to attenuate the inhibition of cell growth and motility induced by miR-497 (37). In addition, it was found that miR-143 acted as a tumor suppressor in human prostate cancer by targeting HK2 (38). In the present study, miR-615 also inhibited the progression of OS by targeting HK2. All these findings prove the accuracy of our results concerning the relationship between miR-615 and HK2 in OS. Although we analyzed the role of miR-615 in the progression of OS, its detailed regulatory network in OS still needs further exploration.

In conclusion, our study reports the inhibitory effect of miR-615 on OS cell viability and metastasis. In addition, miR-615 acts as a tumor suppressor in OS by targeting HK2. Meanwhile, miR-615 blocks EMT and inactivates the PI3K/AKT pathway in OS. These findings suggest that miR-615 may be a new target for the treatment of OS.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

The datasets used during the present study are available from the corresponding author upon reasonable request.

Authors' contributions

LS and JM conceived and designed the study. PW, ZZ, and KZ performed the experiments. LS wrote the paper. ZX and SL reviewed and edited the manuscript. All authors read and approved the manuscript and agree to be accountable for all aspects of the research in ensuring that the accuracy or integrity of any part of the work are appropriately investigated and resolved.

Ethics approval and consent to participate

All of the patients in the present study provided informed consent. Approval for this research was acquired from the Institutional Ethics Committee of Shandong Provincial Third Hospital (2016SPT-44).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Clark JC, Dass CR and Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 134: 281-297, 2008.
2. Luetke A, Meyers PA, Lewis I and Juergens H: Osteosarcoma treatment—where do we stand? A state of the art review. Cancer Treat Rev 40: 523-532, 2014.
3. Shao Y, Geng Y, Gu W, Huang J, Pei H and Jiang J: Prognostic role of tissue and circulating microRNA-200c in malignant tumors: A systematic review and meta-analysis. Cell Physiol Biochem 35: 1188-1200, 2015.
4. Brelack SS, Hecker-Nolting S, Blattmann C and Kager L: Advances in the management of osteosarcoma. F1000Res 5: 2767, 2016.
5. Dalmay T: Mechanism of microRNA-mediated repression of mRNA translation. Essays Biochem 54: 29-38, 2013.
6. van Kouwenhove M, Kedde M and Agami R: MicroRNA regulation by RNA-binding proteins and its implications for cancer. Nat Rev Cancer 11: 644-656, 2011.
7. Nugent M: microRNA and bone cancer. Adv Exp Med Biol 889: 201-230, 2015.
8. Rebei AL, Zhang L, Fu XY, Mu WB, Yang DS, Liu Y, Zhou SJ and Younous A: MicroRNA-214 functions as an oncogene in human osteosarcoma by targeting TRAF3. Eur Rev Med Pharmacol Sci 22: 5156-5164, 2018.
9. Xie W, Xiao J, Wang T, Zhang D and Li Z: MicroRNA-876-5p inhibits cell proliferation, migration and invasion by targeting c-Met in osteosarcoma. J Cell Mol Med 23: 3293-3301, 2019.
10. Wang J, Liu L, Sun Y, Xue Y, Qu J, Pan S, Li H, Qu H, Wang J and Zhang J: miR-615-3p promotes proliferation and migration and inhibits apoptosis through its potential target CELF2 in gastric cancer. Biomed Pharmacother 101: 406-413, 2018.
11. Chen L, Nan A, Zhang N, Jia Y, Li X, Ling Y, Dai J, Zhang S, Yang Q, Yi Y and Jiang Y: Circular RNA 100146 functions as an oncogene through direct binding to miR-361-3p and miR-615-5p in non-small cell lung cancer. Mol Cancer 18: 13, 2019.
12. Wang Q, Wu G, Zhang Z, Tang Q, Zheng W, Chen X, Chen F, Li Q and Che X: Long non-coding RNA HOTTIP promotes renal cell carcinoma progression through the regulation of the miR-615/IGF-2 pathway. Int J Oncol 53: 2278-2288, 2018.
13. Yang B, Xie R, Wu SN, Gao CC, Yang XZ and Zhou JF: MicroRNA-615-5p targets insulin-like growth factor-2 and exerts tumor-suppressing functions in human esophageal squamous cell carcinoma. Oncol Rep 39: 255-263, 2018.
14. Zhong JT and Zhou SH: Warburg effect, hexokinase-II, and radiore sistance of laryngeal carcinoma. Oncotarget 8: 14133-14146, 2017.
15. Jiao L, Zhang HL, Li DD, Yang KL, Tang J, Li X, Ji J, Yu Y, Wu JY, Ravichandran S, et al: Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 (hexokinase 2). Autophagy 14: 671-684, 2018.
16. Zhang Z, Huang S, Wang H, Wu J, Chen D, Peng B and Zhou Q: High expression of hexokinase domain containing 1 is associated with poor prognosis and aggressive phenotype in hepatocarcinoma. Biochem Biophys Res Commun 474: 673-679, 2019.
17. Wei L, Zhou Y, Dai Q, Qiao C, Zhao L, Hui H, Lu N and Guo QL: Oroxylin A induces dissociation of hexokinase II from the mitochondria and inhibits glycolysis by SIRT3-mediated deacetylation of cyclophilin D in breast carcinoma. Cell Death Dis 4: e601, 2013.
18. Xi F and Ye J: Inhibition of lung carcinoma A549 cell growth by knockdown of hexokinase 2 in situ and in vivo. Oncol Res 23: 53-59, 2016.
19. Mukherjee A, Ma Y, Yuan F, Gong Y, Fang Z, Mohamed EM, Bertozzi E, Shao H and Fang X: Lysophosphatidic acid up-regulates hexokinase II and glycolysis to promote proliferation of ovarian cancer cells. Neoplasia 17: 723-734, 2015.
20. Lu J, Wang L, Chen W, Wang Y, Zhen S, Chen H, Cheng J, Zhou Y, Li X and Zhao L: miR-603 targeted hexokinase-2 to inhibit the malignancy of ovarian cancer cells. Arch Biochem Biophys 661: 1-9, 2019.

21. Zhang T, Zhu X, Wu H, Jiang K, Zhao G, Shaukat A, Deng G and Qiu C: Targeting the ROS/PI3K/AKT/HIF-1α/HK2 axis of breast cancer cells: Combined administration of Polypatin and 2-Deoxy-d-glucose. J Cell Mol Med 23: 3711-3723, 2019.

22. Fu JH, Yang S, Nan CJ, Zhou CC, Lu DQ, Li S and Mu HQ: MiR-182 affects renal cancer cell proliferation, apoptosis, and invasion by regulating PI3K/AKT/mTOR signaling pathway. Eur Rev Med Pharmacol Sci 22: 350-361, 2018.

23. Guanen Q, Junjie S, Baolin W, Chaoyang W, Yajuan Y, Jing L, Junpeng L, Gaili N, Zhongping W and Jun W: MiR-214 promotes cell metastasis and inhibites apoptosis of esophageal squamous cell carcinoma via PI3K/AKT/mTOR signaling pathway. Biomed Pharmacother 105: 350-361, 2018.

24. Xu RD, Feng F, Yu XS, Liu ZD and Lao LF: miR-149-5p inhibits cell growth by regulating TWEAK/Fn14/PI3K/AKT pathway and predicts favorable survival in human osteosarcoma. Int J Immunopathol Pharmacol 32: 20189536, 2018.

25. Zhang Z, Luo G, Yu C, Yu G, Jiang R and Shi X: MicroRNA-493-5p inhibits proliferation and metastasis of osteosarcoma cells by targeting Kruppel-like factor 5. J Cell Physiol 234: 13525-13533, 2019.

26. Dong Y, Hua X, Sun R, Liu Z, Huang M and Yang S: IncRNA Gm15290 promotes cell proliferation and invasion in lung cancer through directly interacting with and suppressing the tumor suppressor miR-615-5p. BioSci Rep 38: BSR20181150, 2018.

27. Gao W, Gu Y, Li Z, Cai H, Peng Q, Tu M, Kondo Y, Shinjo K, Zhu Y, Zhang J, et al: miR-615-5p is epigenetically inactivated and functions as a tumor suppressor in pancreatic ductal adenocarcinoma. Oncogene 34: 1629-1640, 2015.

28. Ji Y, Sun Q, Zhang J and Hu H: MiR-615 inhibits cell proliferation, migration and invasion by targeting EGFR in human glioblastoma. Biochem Biophys Res Commun 499: 719-726, 2018.

29. Huang F, Zhao H, Du Z and Jiang H: miR-615 inhibits prostate cancer cell proliferation and invasion by directly targeting cyclin D2. Oncol Res 27: 293-299, 2019.

30. Liu J, Jia Y, Jia L, Li T, Yang L and Zhang G: MicroRNA-615-3p inhibits the tumor growth and metastasis of NSCLC via inhibiting IGF2. Oncol Res 27: 269-279, 2019.

31. Bai Y, Li J, Li J, Liu Y and Zhang B: MiR-615 inhibited cell proliferation and cell cycle of human breast cancer cells by suppressing of AKT2 expression. Int J Clin Exp Med 8: 3801-3808, 2015.

32. Liu H, Liu N, Cheng Y, Jin W, Zhang P, Wang X, Yang H, Xu X, Wang Z and Tu Y: Hexokinase 2 (HK2), the tumor promoter in glioma, is downregulated by miR-218/Bmi1 pathway. PLoS One 12: e0189353, 2017.

33. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25: 402-408, 2001.

34. Snezhkina AV, Krasnov GS, Zhikrivetskaya SO, Karpova IY, Fedorova MS, Nyushko KM, Belyakov MM, Gnuchev NV, Sidorov DV, Alekseev BY, et al: Overexpression of microRNAs miR-9, -98, and -199 correlates with the downregulation of HK2 expression in colorectal cancer. Mol Biol (Mosk) 52: 220-230, 2018 (In Russian).

35. Li W, Hao J, Zhang L, Cheng Z, Deng X and Shu G: Astragaloside reduces hexokinase 2 through increasing miR-125b to inhibit the proliferation of hepatocellular carcinoma cells in vitro and in vivo. J Agric Food Chem 65: 5961-5972, 2017.

36. Gregersen LH, Jacobsen A, Frankel LB, Wen J, Krogh A and Lund AH: MicroRNA-143 down-regulates hexokinase 2 in colon cancer cells. BMC Cancer 12: 232, 2012.

37. Song J, Wu X, Liu F, Li M, Sun Y, Wang Y, Wang C, Zhu K, Jia X, Wang B and Ma X: Long non-coding RNA PVT1 promotes glycolysis and tumor progression by regulating miR-497/HK2 axis in osteosarcoma. Biochem Biophys Res Commun 490: 217-224, 2017.

38. Zhou P, Chen WG and Li XW: MicroRNA-143 acts as a tumor suppressor by targeting hexokinase 2 in human prostate cancer. Am J Cancer Res 5: 2056-2063, 2015.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.